Mycoplasma genitalium and Trichomonas vaginalis in France: a point prevalence study in people screened for sexually transmitted diseases. (February 2017)

• Record Type: Journal Article
• Authors: Arfeuille, C.; Beby-Defaux, A.; Berçot, B.; Boisset, S.; Bourgeois, N.; Carles, M.-J.; Decré, D.; Garand, A.-L.; Gibaud, S.-A.; Grob, A.; Jeannot, K.; Kempf, M.; Moreau, F.; Petitjean-Lecherbonnier, J.; Prère, M.-F.; Salord, H.; Verhoeven, P.; Pereyre, S.; Laurier Nadalié, C.; Bébéar, C.
• Is Part Of: Clinical microbiology and infection. Volume 23:Number 2(2017)
• Page Start: 122.e1
• Page End: 122.e7
• Publication Date: 2017-02
• Subjects: France -- Mycoplasma genitalium -- Prevalence -- Screening -- Trichomonas vaginalis; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2016.10.028
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Objective: Mycoplasma genitalium and Trichomonas vaginalis are common causes of sexually transmitted infections, but limited prevalence data are available in France. We aimed to evaluate the prevalence of M. genitalium and T. vaginalis infections and to assess prevalence by gender, age, sample collection sites and clinical symptoms. A multicentre collection of specimens was intended to obtain a nationwide overview of the epidemiology. Methods: Between September 2014 and January 2015, a total of 2652 consecutive urogenital specimens submitted to the microbiology diagnostic departments of 16 French university hospitals for Chlamydia trachomatis and Neisseria gonorrhoeae detection were collected. M. genitalium and T. vaginalis prevalence were evaluated using a commercial real-time PCR kit. Clinical data from patients were anonymously collected. Results: T. vaginalis and M. genitalium prevalence were 1.7% (95% confidence interval 1.3–2.4) and 3.4% (95% confidence interval 2.8–4.2), respectively, and did not differ between gender or age groups, except M. genitalium prevalence between men and women in the 35- to 44-year age group (5.9 vs. 1.5%; p 0.03). M. genitalium prevalence was significantly higher in patients receiving care in sexually transmitted infection clinics, abortion centres, family planning clinics and prisons than in gynaecologic, obstetric and reproduction centres (4.0 vs. 1.7%, p 0.009). Among M. genitalium – and T. vaginalis –positive patients, 70.9 and 61.5% were asymptomatic, respectively. Conclusions: The low T. vaginalis prevalence does not justify systematic screening for this organism in France. Conversely, selective screening for M. genitalium may be warranted in care settings that receive presumably high-risk sexual behaviour patients, regardless of symptoms.